Free Trial

Palvella Therapeutics (PVLA) Competitors

Palvella Therapeutics logo
$38.62 -0.01 (-0.03%)
As of 04:00 PM Eastern

PVLA vs. AUPH, CVAC, PHVS, WVE, CALT, NTLA, ABCL, GPCR, ARDX, and ELVN

Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Pharvaris (PHVS), WAVE Life Sciences (WVE), Calliditas Therapeutics AB (publ) (CALT), Intellia Therapeutics (NTLA), AbCellera Biologics (ABCL), Structure Therapeutics (GPCR), Ardelyx (ARDX), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.

Palvella Therapeutics vs. Its Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Aurinia Pharmaceuticals has a net margin of 16.11% compared to Palvella Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals16.11% 14.27% 9.93%
Palvella Therapeutics N/A -60.29%-43.30%

Aurinia Pharmaceuticals currently has a consensus target price of $11.50, indicating a potential upside of 28.78%. Palvella Therapeutics has a consensus target price of $47.50, indicating a potential upside of 22.99%. Given Aurinia Pharmaceuticals' higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Palvella Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Aurinia Pharmaceuticals has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$247.30M4.88$5.75M$0.2831.89
Palvella Therapeutics$42.81M9.98-$17.43M-$12.10-3.19

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.93 beat Palvella Therapeutics' score of 0.87 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurinia Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palvella Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

Summary

Aurinia Pharmaceuticals beats Palvella Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PVLA vs. The Competition

MetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$427.14M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-3.1921.1828.1120.03
Price / Sales9.98339.43461.37103.88
Price / CashN/A43.2336.5559.01
Price / Book6.928.368.655.90
Net Income-$17.43M-$55.19M$3.25B$258.66M
7 Day Performance30.87%5.89%4.21%2.22%
1 Month Performance80.97%17.63%10.82%12.76%
1 Year PerformanceN/A5.09%34.70%19.36%

Palvella Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PVLA
Palvella Therapeutics
1.4251 of 5 stars
$38.62
0.0%
$47.50
+23.0%
N/A$427.14M$42.81M-3.19N/A
AUPH
Aurinia Pharmaceuticals
2.9982 of 5 stars
$8.85
-1.6%
$11.50
+29.9%
+63.1%$1.21B$235.13M24.30300Upcoming Earnings
CVAC
CureVac
4.7508 of 5 stars
$5.48
+1.3%
$6.83
+24.7%
+51.1%$1.21B$579.18M5.88880Positive News
PHVS
Pharvaris
1.44 of 5 stars
$23.00
+0.0%
$36.20
+57.4%
+12.3%$1.20BN/A0.0030News Coverage
WVE
WAVE Life Sciences
4.5582 of 5 stars
$7.82
+1.4%
$20.15
+157.7%
+36.4%$1.20B$108.30M0.00240Positive News
Upcoming Earnings
High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
NTLA
Intellia Therapeutics
4.5172 of 5 stars
$11.96
+4.2%
$33.37
+179.0%
-50.1%$1.19B$57.88M0.00600News Coverage
Insider Trade
ABCL
AbCellera Biologics
2.2255 of 5 stars
$4.06
+3.0%
$8.75
+115.5%
+66.8%$1.18B$28.83M0.00500High Trading Volume
GPCR
Structure Therapeutics
2.952 of 5 stars
$19.60
+1.9%
$76.17
+288.6%
-49.6%$1.10BN/A0.00136Positive News
ARDX
Ardelyx
4.0215 of 5 stars
$4.60
+2.2%
$10.89
+136.7%
-22.4%$1.08B$333.61M0.0090
ELVN
Enliven Therapeutics
2.6313 of 5 stars
$21.46
-0.9%
$41.20
+92.0%
-8.6%$1.06BN/A0.0050Insider Trade

Related Companies and Tools


This page (NASDAQ:PVLA) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners